Universität zu Köln

2022

Gluz, Oleg, Nitz, Ulrike, Kolberg-Liedtke, Cornelia, Prat, Aleix ORCID: 0000-0003-2377-540X, Christgen, Matthias, Kuemmel, Sherko, Mohammadian, Mohammad Parsa, Gebauer, Daniel, Kates, Ronald, Pare, Laia ORCID: 0000-0002-4904-558X, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Wuerstlein, Rachel, Graeser, Monika, Pelz, Enrico, Jozwiak, Katarzyna ORCID: 0000-0002-9614-6586, Zu Eulenburg, Christine, Kreipe, Hans Heinrich and Harbeck, Nadia (2022). De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clin. Cancer Res., 28 (22). S. 4995 - 5004. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265

Grote, Isabel ORCID: 0000-0002-6731-187X, Bartels, Stephan ORCID: 0000-0002-8903-2345, Christgen, Henriette, Radner, Martin, Gronewold, Malte, Kandt, Leonie, Raap, Mieke ORCID: 0000-0001-8338-6209, Lehmann, Ulrich ORCID: 0000-0003-2350-6584, Gluz, Oleg, Graeser, Monika, Kuemmel, Sherko, Nitz, Ulrike, Harbeck, Nadia, Kreipe, Hans and Christgen, Matthias (2022). ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer. Mod. Pathol., 35 (12). S. 1804 - 1812. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1530-0285

Nitz, Ulrike, Gluz, Oleg, Graeser, Monika, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Braun, Michael, Augustin, Doris, Potenberg, Jochem, Krauss, Katja, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Stefek, Andrea, Fischer, Hans Holger, Pelz, Enrico, Zu Eulenburg, Christine, Kates, Ronald, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Harbeck, Nadia (2022). De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol., 23 (5). S. 625 - 636. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Nitz, Ulrike A., Gluz, Oleg, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Christgen, Matthias, Braun, Michael, Aktas, Bahriye ORCID: 0000-0002-5474-051X, Luedtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Schumacher, Claudia, Darsow, Maren, Krauss, Katja, Nuding, Benno, Thill, Marc, Potenberg, Jochem, Uleer, Christoph, Warm, Mathias, Fischer, Hans Holger, Malter, Wolfram, Hauptmann, Michael ORCID: 0000-0001-8539-0148, Kates, Ronald E., Graeser, Monika, Wuerstlein, Rachel, Shak, Steven, Baehner, Frederick, Kreipe, Hans H. and Harbeck, Nadia (2022). Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HP2-Early Breast Cancer. J. Clin. Oncol., 40 (23). S. 2557 - 2572. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

2021

Gluz, Oleg, Scheffen, Iris, Degenhardt, Tom, Marschner, Norbert Walter, Christgen, Matthias, Kreipe, Hans Heinrich, Nitz, Ulrike, Kates, Ronald E., Schinkoethe, Timo, Graeser, Monika Karla, Wuerstlein, Rachel, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Bauer, Lelia, Schem, Christian, Fehm, Tanja N., Neubauer, Hans and Harbeck, Nadia (2021). ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker-Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2-early breast cancer. J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Graeser, Monika ORCID: 0000-0003-1916-717X, Feuerhake, Friedrich, Gluz, Oleg, Volk, Valery, Hauptmann, Michael, Jozwiak, Katarzyna, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kolberg-Liedtke, Cornelia, Kates, Ronald, Wuerstlein, Rachel, Nitz, Ulrike, Kreipe, Hans Heinrich and Harbeck, Nadia (2021). Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. J. Immunother. Cancer, 9 (5). LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426

Graeser, Monika ORCID: 0000-0003-1916-717X, Harbeck, Nadia, Gluz, Oleg, Wuerstlein, Rachel, zu Eulenburg, Christine, Schumacher, Claudia, Grischke, Eva -Maria, Forstbauer, Helmut, Dimpfl, Moritz ORCID: 0000-0001-6202-7397, Braun, Michael, Christgen, Matthias, Kreipe, Hans Heinrich, Potenberg, Jochem, von Schumann, Raquel, Aktas, Bahriye, Kolberg-Liedtke, Cornelia, Kuemmel, Sherko ORCID: 0000-0001-9355-494X and Nitz, Ulrike (2021). The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. Breast, 59. S. 58 - 67. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080

Graeser, Monika ORCID: 0000-0003-1916-717X, Schrading, Simone, Gluz, Oleg, Strobel, Kevin, Wuerstlein, Rachel, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Schumacher, Claudia, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Christgen, Matthias, Adams, Jascha, Nitzsche, Henrik, Just, Marianne, Fischer, Hans Holger, Aktas, Bahriye ORCID: 0000-0002-5474-051X, Potenberg, Jochem, Von Schumann, Raquel, Kolberg-Liedtke, Cornelia, Harbeck, Nadia, Kuhl, Christiane K. and Nitz, Ulrike (2021). Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials. Int. J. Cancer, 148 (10). S. 2614 - 2628. HOBOKEN: WILEY. ISSN 1097-0215

Grote, Isabel ORCID: 0000-0002-6731-187X, Bartels, Stephan, Kandt, Leonie, Bollmann, Laura, Christgen, Henriette, Gronewold, Malte, Raap, Mieke, Lehmann, Ulrich, Gluz, Oleg, Nitz, Ulrike, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Zu Eulenburg, Christine, Braun, Michael, Aktas, Bahriye, Grischke, Eva-Maria, Schumacher, Claudia, Luedtke-Heckenkamp, Kerstin, Kates, Ronald, Wuerstlein, Rachel, Graeser, Monika, Harbeck, Nadia, Christgen, Matthias and Kreipe, Hans (2021). TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Med., 10 (23). S. 8581 - 8595. HOBOKEN: WILEY. ISSN 2045-7634

Richters, Lisa Katharina Katharina, Gluz, Oleg, Weber-Lassalle, Nana, Christgen, Matthias, Haverkamp, Heinz, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Kayali, Mohamad ORCID: 0000-0003-2092-5695, Kates, Ronald E., Grischke, Eva-Maria, Braun, Michael, Warm, Mathias, Wuerstlein, Rachel, Ernst, Corinna, Graeser, Monika Karla, Hauke, Jan, Nitz, Ulrike, Kreipe, Hans Heinrich, Schmutzler, Rita K., Hahnen, Eric and Harbeck, Nadia (2021). Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242). J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

2020

Christgen, Matthias, Gluz, Oleg, Harbeck, Nadia, Kates, Ronald E., Raap, Mieke, Christgen, Henriette, Clemens, Michael, Malter, Wolfram, Nuding, Benno, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Stefek, Andrea, Krabisch, Petra, Just, Marianne, Augustin, Doris, Graeser, Monika, Baehner, Frederick, Wuerstlein, Rachel, Nitz, Ulrike and Kreipe, Hans (2020). Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer. Cancer, 126 (22). S. 4847 - 4859. HOBOKEN: WILEY. ISSN 1097-0142

Dowsett, Mitch, Ellis, Matthew J., Dixon, J. Michael, Gluz, Oleg, Robertson, John, Kates, Ronald, Suman, Vera J., Turnbull, Arran K., Nitz, Ulrike, Christgen, Matthias, Kreipe, Hans, Kuemmel, Sherko, Bliss, Judith M., Barry, Peter, Johnston, Stephen R., Jacobs, Samuel A., Ma, Cynthia X., Smith, Ian E. and Harbeck, Nadia (2020). Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. npj Breast Cancer, 6 (1). LONDON: NATURE PUBLISHING GROUP. ISSN 2374-4677

Gluz, Oleg, Kolberg-Liedtke, Cornelia, Prat, Aleix ORCID: 0000-0003-2377-540X, Christgen, Matthias, Gebauer, Daniel, Kates, Ronald, Pare, Laia ORCID: 0000-0002-4904-558X, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Pelz, Enrico, Nitz, Ulrike, Kreipe, Hans Heinrich and Harbeck, Nadia (2020). Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. Int. J. Cancer, 146 (1). S. 262 - 272. HOBOKEN: WILEY. ISSN 1097-0215

Gluz, Oleg, Nitz, Ulrike, Christgen, Matthias, Kuemmel, Sherko, Holtschmidt, Johannes, Priel, Jan, Hartkopf, Andreas, Potenberg, Jochem, Luedtke-Heckenkamp, Kerstin, Just, Marianne, Wuelfing, Pia, Von Schumann, Raquel, Graeser, Monika, Wuerstlein, Rachel, Kates, Ronald E., Kreipe, Hans Heinrich and Harbeck, Nadia (2020). De-escalated chemotherapy versus endocrine therapy plus pertuzumab plus trastuzumab for HR+/HER2+early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Nitz, Ulrike, Gluz, Oleg, Kreipe, Hans H., Christgen, Matthias, Kuemmel, Sherko, Baehner, Frederick L., Shak, Steven, Aktas, Bahriye, Braun, Michael, Ludtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Nuding, Benno, Darsow, Maren, Schumacher, Claudia, Krauss, Katja, Malter, Wolfram, Thill, Marc, Warm, Mathias, Wuerstlein, Rachel, Kates, Ronald E. and Harbeck, Nadia (2020). The run-in phase of the prospective WSG-ADAPT HR+/HER2-trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. Ther. Adv. Med. Oncol., 12. LONDON: SAGE PUBLICATIONS LTD. ISSN 1758-8359

2019

Christgen, Matthias, Bartels, Stephan ORCID: 0000-0002-8903-2345, Radner, Martin, Raap, Mieke, Rieger, Luisa, Christgen, Henriette, Gluz, Oleg, Nitz, Ulrike, Harbeck, Nadia, Lehmann, Ulrich and Kreipe, Hans (2019). ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling. Gene Chromosomes Cancer, 58 (3). S. 175 - 186. HOBOKEN: WILEY. ISSN 1098-2264

Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Nitz, U., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M. and Walter-Kirst, R. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J. Clin. Oncol., 37 (10). S. 799 - 811. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

2018

Gluz, Oleg, Liedtke, Cornelia, Prat, Aleix, Christgen, Matthias, Gebauer, Daniel, Kates, Ronald, Pelz, Enrico, Clemens, Michael, Warm, Matthias, Aktas, Bahriye, Kuemmel, Sherko, Pare, Laia, Krabisch, Petra, Kreipe, Hans Heinrich, Wuerstlein, Rachel, Nitz, Ulrike and Harbeck, Nadia (2018). Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: Results from the prospective WSG PlanB trial. Cancer Res., 78 (4). PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Gluz, Oleg, Nitz, Ulrike, Liedtke, Cornelia, Christgen, Matthias, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Bangemann, Nikola, Lindner, Christoph, Kuemmel, Sherko, Clemens, Michael, Potenberg, Jochem, Staib, Peter, Kohls, Andreas, von Schumann, Raquel and Harbeck, Nadia (2018). Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. JNCI-J. Natl. Cancer Inst., 110 (6). S. 628 - 638. CARY: OXFORD UNIV PRESS INC. ISSN 1460-2105

Harbeck, Nadia, Nitz, Ulrike, Christgen, Matthias, Kates, Ronald E., Braun, Michael Wilhelm, Kummel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, Kleine-Tebbe, Anke, Liedtke, Cornelia, de Haas, Sanne, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Gluz, Oleg (2018). Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

2017

Harbeck, Nadia, Gluz, Oleg, Christgen, Matthias, Kates, Ronald Ernest, Braun, Michael, Kueemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Kraemer, Stefan, Kleine-Tebbe, Anke, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, von Schumann, Raquel, Liedtke, Cornelia, Grischke, Eva-Maria, Schumacher, Johannes, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Nitz, Ulrike Anneliese (2017). De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J. Clin. Oncol., 35 (26). S. 3046 - 3057. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Harbeck, Nadia, Gluz, Oleg, Clemens, Michael R., Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kummel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald, Kreipe, Hans Heinrich and Nitz, Ulrike (2017). Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC -> 4x doc vs. 6x docetaxel/cyclophospham ide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. J. Clin. Oncol., 35. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Nitz, Ulrike, Gluz, Oleg, Christgen, Matthias, Kates, Ronald E., Clemens, Michael, Malter, Wolfram, Nuding, Benno, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Stefek, Andrea, Lorenz-Salehi, Fatemeh, Krabisch, Petra, Just, Marianne, Augustin, Doris, Liedtke, Cornelia, Chao, Calvin, Shak, Steven, Wuerstlein, Rachel, Kreipe, Hans H. and Harbeck, Nadia (2017). Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res. Treat., 165 (3). S. 573 - 584. NEW YORK: SPRINGER. ISSN 1573-7217

2016

Degenhardt, Tom, Kreipe, Hans Heinrich, Gluz, Oleg, Kates, Ronald E., Liedtke, Cornelia, Kraemer, Stefan, Clemens, Michael R., Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Stefek, Andrea, Heyl, Volker, Wuerstlein, Rachel, Nitz, Ulrike, Harbeck, Nadia and Christgen, Matthias (2016). Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Gluz, Oleg, Nitz, Ulrike, Christgen, Matthias, Kates, Ronald E., Clemens, Michael, Kraemer, Stefan, Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Stefek, Andrea, Lorenz-Salehi, Fatemeh, Krabisch, Petra, Liedtke, Cornelia, Svedman, Christer, Shak, Steven, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Harbeck, Nadia (2016). Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2-early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Gluz, Oleg, Nitz, Ulrike A., Christgen, Matthias, Kates, Ronald E., Shak, Steven, Clemens, Michael, Kraemer, Stefan, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Kusche, Manfred, Heyl, Volker, Lorenz-Salehi, Fatemeh, Just, Marianne, Hofmann, Daniel, Degenhardt, Tom, Liedtke, Cornelia, Svedman, Christer, Wuerstlein, Rachel, Kreipe, Hans H. and Harbeck, Nadia (2016). West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. J. Clin. Oncol., 34 (20). S. 2341 - 2353. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

2015

Mueller, Philipp, Kreuzaler, Matthias, Khan, Tarik, Thommen, Daniela S., Martin, Kea, Glatz, Katharina, Savic, Spasenija, Harbeck, Nadia, Nitz, Ulrike, Gluz, Oleg, von Bergwelt-Baildon, Michael, Kreipe, Hans, Reddy, Sai ORCID: 0000-0002-9177-0857, Christgen, Matthias and Zippelius, Alfred (2015). Trastuzumab emtansine (T-DM1) renders HER2(+) breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci. Transl. Med., 7 (315). WASHINGTON: AMER ASSOC ADVANCEMENT SCIENCE. ISSN 1946-6242